Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy by ZiCheng Zhang et al.
Zhang et al. Radiation Oncology 2014, 9:54
http://www.ro-journal.com/content/9/1/54RESEARCH Open AccessRisk factors of radiation-induced acute esophagitis
in non-small cell lung cancer patients treated with
concomitant chemoradiotherapy
ZiCheng Zhang1,2,3,4, Jin Xu2,1,4, Tao Zhou2, Yan Yi2, HongSheng Li2, HongFu Sun2, Wei Huang2, DongQing Wang2,
BaoSheng Li2,4* and GuoGuang Ying1,3,4*Abstract
Background: To analyze the clinical and dosimetric risk factors of acute esophagitis (AE) in non-small-cell lung
cancer (NSCLC) patients treated with concomitant chemoradiotherapy.
Methods: Seventy-six NSCLC patients treated with concomitant chemoradiotherapy were retrospectively analyzed.
Forty-one patients received concomitant chemoradiotherapy with vinorelbine/cisplatin (VC), 35 with docetaxel/cisplatin
(DC). AE was graded according to criteria of the Radiation Therapy Oncology Group (RTOG). The following clinical and
dosimetric parameters were analyzed: gender, age, clinical stage, Karnofsky performance status (KPS), pretreatment
weight loss, concomitant chemotherapy agents (CCA) (VC vs. DC), percentage of esophagus volume treated to ≥20
(V20), ≥30 (V30), ≥40 (V40), ≥50 (V50) and ≥60 Gy (V60), and the maximum (Dmax) and mean doses (Dmean)
delivered to esophagus. Univariate and multivariate logistic regression analysis were used to test the association
between the different factors and AE.
Results: Seventy patients developed AE (Grade 1, 19 patients; Grade 2, 36 patients; and Grade 3, 15 patients). By
multivariate logistic regression analysis, V40 was the only statistically significant factor associated with Grade ≥2 AE
(p<0.001, OR = 1.159). A V40 of <23% had a 33.3% (10/30) risk of Grade ≥2 AE, which increased to 89.1% (41/46) with a
V40 of ≥23% (p<0.001). CCA (p =0.01; OR = 9.686) and V50 (p<0.001; OR = 1.122) were most significantly correlated
with grade 3 AE. A V50 of <26.5% had a 6.7% (3/45) risk of Grade 3 AE, which increased to 38.7% (12/31) with a
V50 of ≥26.5% (p = 0.001). On the linear regression analysis, V50 and CCA were significant independent factors
affecting AE duration. Patients who received concomitant chemotherapy with VC had a decreased risk of grade 3
AE and shorter duration compared with DC.
Conclusions: Concomitant chemotherapy agents have potential influence on AE. Concomitant chemotherapy
with VC led to lower risk of AE compared with that using DC. V40 and V50 of esophagus can predict grade ≥2
and ≥3 AE, respectively.
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Lung cancer is currently the most common malignancy
and also the leading cause of cancer-related mortality in
the world [1]. Non-small cell lung cancer (NSCLC) ac-
counts for approximately 85% of all lung cancers [2].
About one third of patients with NSCLC present with lo-
cally advanced disease at the time of diagnosis [3]. The
recommended treatment of patients presenting with inop-
erable stage-III NSCLC and a good performance score is
concomitant chemoradiotherapy [4]. But the use of con-
current chemoradiation increases the risk of esophagitis,
which remains the primary radiation-related toxicity [5].
At present, a two-drug regimen combining a platinum
agent with either vinorelbine or docetaxel is considered as
the standard practice of chemoradiotherapy for local ad-
vanced or advanced NSCLC. Whether the severity of AE
is influenced by concomitant chemotherapy agent (CCA)
is uncertain. The purpose of this work was to perform
prospective study to determine risk factors for AE in
NSCLC patients treated with radiation combined with VC
or DC concomitant chemotherapy.
Methods
Patients
Between October 2006 and March 2009, 76 patients diag-
nosed with NSCLC were enrolled in this study. All patients
had histologically or cytological proven NSCLC (40 patients
had squamous-cell carcinoma, 32 adenocarcinoma, 1 ade-
nosquamous carcinoma, 1 large cell carcinoma, 2 others).
There were 59 men and 17 women. The median age was
59 years (range, 33–77 years). All patients were staged ac-
cording to the AJCC 2002 classification. Three patients had
stage II, 32 stage IIIa, 37 stage IIIb, and 4 stage IV. Of these
patients, 11 patients had undergone surgical intervention
before chemoradiotherapy.
Chemotherapy
All patients received concomitant chemoradiotherapy,
which were administered by medical oncologists accord-
ing to our institutional standards. Of these patients, 41 re-
ceived concomitant chemotherapy with VC, 35 with DC.
Concomitant chemotherapy regimens were summarized
in the Table 1. Seventy-three patients had been treated
with concomitant chemotherapy starting on the first day
of radiation therapy, 3 on the second day. Twelve patientsTable 1 Concomitant chemotherapy regimens (n = 76)
Concomitant chemotherapy regimens
Vinorelbine (20 mg/m2, days 1, 8) and cisplatin (25 mg/m2, day 1,2,3), every 2
Vinorelbine (25 mg/m2, days 1, 8) and cisplatin (25 mg/m2, day 1,2,3), every 2
Docetaxel (30 mg/m2, days 1, 8) and cisplatin (25 mg/m2, day 1,2,3), every 21
Docetaxel (35 mg/m2, days 1, 8) and cisplatin (25 mg/m2, day 1,2,3), every 21
Docetaxel (40 mg/m2, days 1,8) and cisplatin (25 mg/m2, day 1,2,3), every 21had received induction chemotherapy. After completion of
radiotherapy, 71 patients received consolidation chemo-
therapy in our institution, and 5 patients were followed up.
Radiotherapy treatment and dosimetric parameters
Seventy-one patients were treated with three-dimensional
conformal radiotherapy (3D-CRT), 5 with intensity modu-
lated radiation therapy (IMRT). Patients were set up in
treatment position and immobilized using vacuum bag to
improve the reproducibility during daily treatments. Com-
puted Tomography (CT) scans with a slice thickness of
5 mm thick was obtained from the lower end of the cri-
coid cartilage to the lower edge of the liver. The obtained
CT images were directly transmitted to a 3D planning sys-
tem (Pinnacle3, Philips Medical Systems). Gross tumor
volume (GTV) was delineated to encompass all detectable
tumors, including primary mass and metastatic regional
lymph nodes observed on CT. Planning target volume
(PTV) included GTV and margins of 5 to 12 mm for
lymph nodes, 8 to 20 mm for primary tumor. Fifty-eight
patients (76.3%) were treated with involved-field irradi-
ation, 18 (23.7%) with elective nodal irradiation. The exter-
nal surface of the esophagus was contoured uniformly on
each of the axial images of the planning CT by the same
physician. The normal esophagus was defined from the in-
ferior border of the cricoid cartilage to the gastroesopha-
gea junction. All patients were treated with conventional
fractionation scheme, 5 days per week, with fractional
dose of 2.0 Gy for 70 patients and 1.8 Gy for 6 patients.
The median of fraction number was 30, ranging 28–35. At
least 90% of a PTV was required to be covered by the pre-
scription dose. Dose constraints for normal tissue used in
the planning process were as follows: V20 < 33% (i.e., ≤
33% of total lung volume received ≥ 20 Gy), and spinal
cord Dmax < 48 Gy. No dose limits were used for the
esophagus, trachea, and heart. Dose distribution was calcu-
lated with tissue heterogeneity correction. A series of dose
volume parameters including Dmean, Dmax, V20, V30,
V40, V50 and V60 were recorded for normal structures.
Radiotherapy was delivered with linear accelerators using 6
or 15-MV X-rays. Treatment techniques typically included
initial anterior-posterior beams followed by oblique off-
cord beams. Most of plans employed 4 to 6 fields. Respir-
ation motion was managed by using the Active Breathing
Coordinator device (Elekta Inc.) for 18 patients (23.7%).Cycles Patients number (n)
1 days. 2 5
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fields (18 cm× 18 cm) with 18 monitor units were used to
guide daily patient positioning for 32 patients (42.1%), while
cone-beam CTs were used to position patient at the first
three treatments and once a week subsequently for 44
patients (57.9%).
Clinical evaluation and follow-up
All patients were hospitalized during the course of radio-
therapy, and were seen everyday as routine evaluation of
the treatment. After completion of therapy, patients were
followed up every month for the first 3 months and every
3 or 4 months thereafter. If necessary, telephone follow-up
was conducted to acquire more information on radiation
induced toxicity. AE (measured within 3 months of initiat-
ing radiotherapy) were evaluated according to the RTOG
and European Organization for Research and Treatment
of Cancer toxicity grading scale [6]. These data, including
complaints of patients, the maximum toxicity grade, the
first day of symptoms appeared and the first day of symp-
toms disappeared were recorded. Duration of AE was the
gap between the first day of symptoms disappeared and
the first day of symptoms appeared.
Statistical analysis
The maximal grade and the AE duration for each patient
were used in the statistical analysis. A descriptive statistical
analysis was performed and results are reported as mean ±
Standard deviation (SD) for continuous variable. The corre-
lations among dosimetric parameters were assessed with
Pearson Correlation coefficient test. The difference of dosi-
metric parameters between VC group and DC group were
evaluated by t test. Mann–Whitney U test was used to ver-
ify the difference of occurring time. Patients experiencing
grade 2 or worse, grade 3 or worse, were counted as posi-
tive events. The following factors: gender (male vs. female),
age (continuous), clinical stage (≤IIIa vs. ≥IIIb), KPS (<90
vs. ≥90), pretreatment weight loss (<5% vs. ≥5%), CCA (VC
vs. DC), Dmean, Dmax, V20, V30, V40, V50 and V60, were
included in the statistical analysis. Univariate logistic re-
gression analysis was used to test the association between
the different factors and positive events (Grade ≥2 AE,
Grade ≥3 AE). Pearson correlation analysis was used to
correlate these parameters with duration (continuous). For
multivariate analysis, the forward Wald procedure was per-
formed using a logistic regression model containing all sta-
tistically significant variables in univariate analysis (p<0.10).
Receiver operating characteristic (ROC) curves have been
used to identify discriminate threshold. Linear regression
model was used to evaluate their importance in duration
(continuous). All statistical tests were 2-sided. Statistically
significant differences are reported for p<0.05. Statistical
analyses were performed using SPSS (version 15.0 for
Windows).Results and discussion
Results
Of all patients studied, fifteen patients experienced inter-
ruption in radiotherapy delivery, 5 due to AE (3 in DC
group, 2 in VC group), 7 due to neutropenia, and 3 due to
machine problems. For patients with radiotherapy interrup-
tions, the median delay was 3 days (range, 1-5 days). After
completion of radiotherapy, fifteen patients experienced
delay of consolidation chemotherapy, 6 for neutropenia, 6
for AE (4 in DC group, 2 in VC group), 1 for transami-
nases, and 2 for refusal of patient. The median delay was
5 days (range, 1–13).
The mean ± SD of radiation dose to PTV was 60.7 ±
2.6 Gy (median 60Gy; range, 56–66 Gy). VC group had
slightly numerically higher dosimetric parameters of
esophagus than DC group, but there were no statistical
difference by t test (p:0.293-0.616). Most of dosimetric pa-
rameters were closely correlated with one another when
assessed by Pearson correlation coefficient test (r:0.439-
0.980; p<0.001) except the correlation between Dmax and
V20(r = 0.173, p = 0.136).
A total of 70 patients (92.1%, 70/76) developed grade ≥1
AE. Among them, 19 patients experienced grade 1 AE
(25.0%, 19/76), 36 grade 2 (47.4%, 36/76) and 15 grade 3
(19.7%, 15/76). No grade 4 or 5 AE was observed. In the
VC group, 5 patients experienced grade 0 (12.2%, 5/41),
11 grade 1 (26.8%, 11/41), 19 grade 2 (46.3%, 19/41) and 6
grade 3 (14.6%, 6/41). In the DC group, 1 patients experi-
enced grade 0 (2.9%, 1/35), 8 grade 1 (22.9%, 8/35), 17
grade 2 (48.6%, 17/35) and 9 grade 3 (25.7%, 9/35).
Predictors for grade ≥2 AE, grade ≥3 AE
Of the clinical factors investigated, such as gender, age,
clinical stage, KPS, pretreatment weight loss and CCA,
none was found to be significant for predicting grade ≥2
or grade 3 AE in univariate analysis (p<0.05). The CCA
(VC vs. DC) was weakly related to grade 3 AE (p =
0.081, OR = 2.880). All dosimetric parameters investi-
gated, including Dmax, Dmean, V20, V30, V40, V50 and
V60 of esophagus, were found to be significantly associ-
ated with the risk of grade ≥2 or grade 3 AE (p<0.05) in
univariate analysis. These results were summarized in
Table 2. All dosimetric parameters were input into the
multivariate logistic regression analysis. CCA was margin-
ally significant and was also included in the multivariate
analysis of grade 3 AE. V40 was found to be the only statis-
tically significant factor associated with Grade ≥2 AE. CCA
and V50 were most significantly correlated with grade 3
AE. Table 3 showed the result of multivariate analysis by
SPSS15.0.
The predictive power of V40 for grade ≥2 AE was tested
by ROC analysis. The areas under the ROC curve for
grade ≥2 AE were 0.888 (95% CI: 0.813-0.963; p<0.001).
These data had been used to identify discrete points on
Table 2 Univariate analysis of dosimetric parameters
associated with AE
Variable Grade ≥ 2 AE Grade ≥ 3 AE
p OR p OR
Dmean (Gy) <0.001 1.002 <0.001 1.001
Dmax (Gy) 0.001 1.001 0.007 1.001
V20 (%) 0.001 1.068 0.01 1.054
V30 (%) <0.001 1.149 0.001 1.069
V40 (%) <0.001 1.159 <0.001 1.087
V50 (%) <0.001 1.138 <0.001 1.097
V60 (%) <0.001 1.124 <0.001 1.094
Abbreviations: AE = acute esophagitis; OR= odds ratio; Dmax the maximum dose
of the esophagus; Dmean = the mean dose of the esophagus; V20,30,40,50,60 =
relative esophageal volume for radiation dose ≥20,30,40,50,60 Gy, respectively.
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sents the cut point with appropriate sensitivity (80.4%)
and specificity (80.0%). If V40 is <23% there is a 33.3%
(10/30) risk of grade ≥2 AE, which increases to 89.1%
(41/46) if V40 is ≥23% (p<0.001).
The predictive ability of V50 to for grade 3 AE was also
tested by ROC analysis. The areas under the ROC curve
for grade 3 AE were 0.841 (95% CI: 0.730-0.952; p<0.001).
In these curves, V50 = 26.5% represents the cut point with
sensitivity (80.0%) and specificity (68.9%). If V50 is <26.5%
there is a 6.7% (3/45) risk of Grade 3 AE, which increases
to 38.7% (12/31) if V50 is ≥26.5% (p = 0.001).Occurring time of AE
All 70 patients experienced grade ≥1 AE were included in
the analysis, 36 in VC group, and 34 in DC group. The me-
dian occurring time was 22 day (ranging 8-41 day) for all
70 patients, 23 day (ranging 9-41 day) for the VC group
(n = 36) and 21.5 day (ranging 8-29 day) for the DC group
(n = 34). There were significantly statistical difference
between VC and DC groups by Mann–Whitney U Test
(Z = −2.465, p = 0.014). Grade ≥1 AE occur later in pa-
tients treated with VC than those with DC. Distribution
of VC and DC group patients according to the occur-
ring time were depicted in Figure 1.Table 3 Multivariate analysis of dosimetric parameters associ
Grade Variable B S.E. Wald
Grade 2 V40 0.148 0.036 17.248
Constant −2.760 0.811 11.574
Grade 3 V50 0.115 0.030 15.204
CCA 2.271 0.886 6.565
Constant −8.389 2.138 15.393
Abbreviations: AE acute esophagitis, CCA concomitant chemotherapy agents (vinore
radiation dose ≥40,50 Gy, respectively.Duration of grade ≥1 AE and its predictors
All 70 patients with grade ≥1 AE were included in the dur-
ation analysis. Dosimetric parameters of VC and DC groups
were summarized in Table 4. There were marginally statis-
tical difference in some dosimetric parameters between VC
group and DC group by t Test (p<0.1). Most dosimetric pa-
rameters for the VC group were higher than those for the
DC group.
The mean ± SD durations of 70 patients suffered
grade ≥1 AE were of 41.2 ± 11.1 days. There were signifi-
cant differences in AE duration between VC group and DC
group by t test (t = −2.931, p = 0.005). A longer duration
(about one week) was found in DC group (45.0 ± 10.9 days)
in comparison to the VC group (37.6 ± 10.3 days).
By Pearson correlation analysis, CCA (r = 0.335, p =
0.005), V20 (r = 0.466, p < 0.001), V30 (r = 0.593, p < 0.001),
V40 (r = 0.628, p < 0.001), V50 (r = 0.650, p < 0.001), V60
(r = 0.599, p < 0.001), Dmax (r = 0.268, p = 0.025) and
Dmean (r = 0.630, p < 0.001) were all significantly correlated
with grade ≥1 AE duration. Figure 2 shows the plot of the
AE duration (days) versus V50 of esophagus for patients
with VC group and DC group. On stepwise multiple linear
regression analysis, V50 and CCA were significant in-
dependent factors affecting grade ≥1 AE duration. Ad-
justed R2 = 0.643. Patients who received concomitant
chemotherapy with VC show a shorter duration compared
with DC. The predictive equation of AE duration was as
follows: Y(days) = 12.195 + 0.512 ×V50 (%) + 10.865 ×CCA,
where V50 (%) = relative esophageal volume for radiation
dose ≥50 Gy and CCA= 1 or 2 for concomitant chemo-
therapy with VC or DC, respectively.
Discussion
AE is one of the main complications of radiotherapy for
NSCLC. Meta-analysis [7] have showed that concomitant
chemoradiotherapy significantly increased grade 3 to 4 AE
as compared with sequential chemoradiotherapy, from 4%
to 18% with a relative risk of 4.9 (95% CI, 3.1 to 7.8; p <
0.001). Severe AE may worsen patients’ quality of life and
cause interruption in their treatments. Predicting AE in
patients treated with concomitant chemoradiotherapy is
essential for clinical treatment planning.ated with AE
df Sig. Exp (B) 95.0% C.I. for EXP (B)
Lower Upper
1 <0.001 1.159 1.081 1.243
1 0.001 0.063
1 <0.001 1.122 1.059 1.189
1 0.010 9.686 1.705 55.016
1 <0.001 <0.001
lbine/cisplatin vs. docetaxel/cisplatin), V40,50 relative esophageal volume for
Figure 1 Distribution of VC and DC group patients according to the occurring time. Abbreviations: VC = vinorelbine/cisplatin;
DC = docetaxel/cisplatin.
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on developing AE. The CALGB study 9431 [8], showed
an attractive result about the effect of CCA on develop-
ing AE. In the phase II study, vinorelbine group had
similar therapeutic efficacy with a lower incidence of
Grade ≥3 esophageal toxicity compared with gemcita-
bine group or paclitaxel group (25% vs. 52% and 39%, re-
spectively). Prior studies on AE involved in a variety of
chemotherapy agents and a mixture of sequential, con-
current, or induction plus concomitant treatment with
thoracic irradiation. In the present study, we reduced
some of these variations. Most of patients had never re-
ceived chemotherapy, and were administrated concomi-
tant chemotherapy at the same scheduling. Based on the
homogeneity, VC group showed lower esophageal tox-
icity in multivariate analysis, based on not only grade
but also duration.
Esophagus is lined by nonkeratinized epithelium with a
lamina propria and muscularis mucosa. AE is one of the
gastrointestinal mucositis (GIM) caused by cancer therap-
ies. Chemotherapy and radiotherapy damage the dividingTable 4 Dosimetric parameter of VC group versus DC group
Factors VC group (n = 36) DC group (n = 34) t p value
Dmean (Gy) 26.2 ± 9.7 22.6 ± 8.5 1.626 0.108
Dmax (Gy) 67.1 ± 5.3 65.2 ± 9.3 1.074 0.288
V20 (%) 48.2 ± 16.2 41.9 ± 13.2 1.782 0.079
V30 (%) 40.6 ± 16.9 33.7 ± 13.7 1.868 0.066
V40 (%) 34.2 ± 16.4 27.6 ± 15.3 1.727 0.089
V50 (%) 28.3 ± 16.2 21.6 ± 16.1 1.747 0.085
V60 (%) 19.2 ± 14.9 14.2 ± 14.6 1.424 0.159
Abbreviations: VC vinorelbine/cisplatin, DC docetaxel/cisplatin, Dmax the maximum
dose of the esophagus, Dmean the mean dose of the esophagus, V20,30,40,50,60 =
relative esophageal volume for radiation dose ≥20,30,40,50,60 Gy, respectively.and differentiating cells and limit the proliferative ability
of the epithelium, so that it becomes thin or ulcerated
[9,10]. Chemotherapy also alters the proliferative rate of
connective tissue cells within the lamina propria, which
results in increased vascular permeability and an inflam-
matory infiltrate [10]. The plethora of rapidly dividing cells
in the gastrointestinal tract makes the tract particularly vul-
nerable to cytotoxic chemotherapeutic agents [11]. Risk of
mucositis has classically been directly associated with mo-
dality, intensity and route of delivery of the cancer therapy
[12]. Significant changes in the agents or doses commonlyFigure 2 AE duration versus V50 of esophagus for patients in
VC group (+) and DC group ( ). Abbreviations: AE = acute
esophagitis; V50 = relative esophageal volume for radiation dose ≥
50 Gy; VC = Vinorelbine/Cisplatin; DC = Docetaxel/Cisplatin.
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mucositis [13]. Certain agents, such as 5-fluorouracil, cape-
citabine, tegafur, methotrexate, irinotecan and the taxanes,
lead to a high rate of GIM [11,12,14]. As for the esophagus,
many patients undergoing chemotherapy with agents such
as methotrexate, 5-fluorouracil, or the taxanes develop
esophagitis [14]. There is little information in the litera-
ture regarding esophageal mucositis because most
symptoms localized to the esophagus usually are attrib-
uted to gastroesophageal reflux disease or to either viral
or fungal infections, which can coexist with any direct
chemotherapy-induced toxicity [10]. At present, there
are a limited number of instruments available for as-
sessment of GIM. These scales typically measure indir-
ect outcomes of mucosal injury, including diarrhea [12].
Several studies reported that docetaxel showed heavy
GIM compared with vinorelbine in NSCLC patients treated
with chemotherapy. In a randomized phase II study of do-
cetaxel or vinorelbine in combination with cisplatin against
NSCLC [15], more patients suffered from diarrhea in the
DC arm than in the VC arm (45.7% grade 1 to 4 vs. 6.3%
grade 1 to 2, p < 0.001). Another phase III study [16] showed
that grade 3 to 4 diarrhea occurred more frequently in DC
(6.7%) and docetaxel/carboplatin (5.2%) patients compared
with VC patients (2.8%), and they had a negligible influence
on treatment delays and treatment discontinuation. In the
epidemiological study of treatment-associated mucosal in-
jury using modified meta-analysis methods, VC regimen
has the lowest incidence of grade 3 or 4 diarrhea (0.25%)
compared with other combined regimens using in NSCLC
[13]. Vinorelbine maybe show gentle GIM within effective
anti-tumor dose range compared with docetaxel.
In the QUANTEC study, Werner-Wasik et al. reviewed
many studies on analyzing dosimetric risk factors of AE,
the results were not consistent [17]. But there was a clear
trend demonstrating that volumes receiving >40-50Gy
correlated significantly with AE [17]. In this study, we
found that V40 and V50 were important predictors of AE.
Kwint et al. [18] reported that the V50 was identified as
the most accurate predictor of grade ≥3 AE for NSCLC
patients treated with IMRT and concurrent chemotherapy.
In this study, we also found that V50 was a significant in-
dependent factor affecting AE duration. This result gener-
ally agrees with those reported by Algara M et al. [19] and
Rodríguez N et al. [20].
Conclusions
Patients who had received concomitant chemotherapy
with VC show statistically lower AE grade, later occur-
ring time and shorter AE duration compared with the
patients treated with DC in the present study. This indi-
cates that the CCA may be a critical influencing factor
of AE in these patients. The analysis of subgroup with
different CCA will be needed in order to explore themost valuable predictor of AE. Dosimetric parameters V40
and V50 were important predictors of grade ≥2 or ≥3 AE,
respectively, for NSCLC patients treated with concomitant
chemoradiotherapy.
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